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Objective To compare the incidence of systemic conditions
between women who had surgical treatment for stress
incontinence with mesh and without mesh.
Design National cohort study.
Setting English National Health Service.
Population Women with no previous record of systemic disease
who had first-time urinary incontinence surgery between 1
January 2006 and 31 December 2013, followed up to the earliest
of 10 years or 31 March 2019.
Methods Competing-risks regression was used to estimate hazard
ratios (HR), adjusted for patient characteristics, with HR > 1
indicating increased incidence following mesh surgery.
Main outcome measures First postoperative admission with a
record of autoimmune disease, fibromyalgia or myalgic
encephalomyelitis up to 10 years following the first incontinence
procedure.
Results The cohort included 88 947 women who had mesh surgery
and 3389 women who had non-mesh surgery. Both treatment
groups were similar with respect to age, socio-economic
deprivation, comorbidity and ethnicity. The 10-year cumulative
incidence of autoimmune disease, fibromyalgia or myalgic
encephalomyelitis was 8.1% (95% CI 7.9–8.3%) in the mesh group
and 9.0% (95% CI 8.0–10.1%) in the non-mesh group (adjusted HR
0.89, 95% CI 0.79–1.01; P = 0.07). A sensitivity analysis including
only autoimmune diseases as an outcome returned a similar result.
Conclusions These findings do not support claims that synthetic
mesh slings cause systemic disease.
Keywords Autoimmune disease, colposuspension, fascial sling,
fibromyalgia, incontinence surgery, midurethral synthetic mesh
sling insertion, myalgic encephalomyelitis, severe adverse events,
stress urinary incontinence, systemic conditions, urogynaecology.
Tweetable abstract No evidence of increased risk of systemic
conditions after stress incontinence treatment with a mesh sling.
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Introduction
Stress urinary incontinence is a common condition affect-
ing up to 40% of postmenopausal women that can have a
significant effect on quality of life.1,2 Conservative treat-
ment options include lifestyle interventions and pelvic floor
muscle training.3 Further treatments include various surgi-
cal options, such as colposuspension, where sutures are
used to elevate the proximal urethra, or a mid-urethral
sling insertion.4 Slings can be made from a length of fascia
harvested from the patient (‘non-mesh’ sling), or from syn-
thetic material (‘mesh’ sling). Mesh slings were introduced
in the 1990s. A randomised controlled trial with a follow-
up period of 6 months, published in 2002, found*Joint senior author.
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comparable effectiveness and a similar risk of complications
with them compared with colposuspension.5 Mesh slings
became the dominant surgical treatment for stress urinary
incontinence in many countries, with over 200 000 mesh
sling insertions performed in the USA in 2010.6 In the Eng-
lish National Health Service (NHS), the annual number of
mesh sling insertions increased to 16 000 in 2009,7 then
subsequently decreased, as reports of harmful adverse
effects increased.8
From 2017, the use of mesh as a treatment of urinary
incontinence was restricted or banned in an increasing
number of countries.9 In 2020 a national review, commis-
sioned by the English Department of Health and Social
Care, reported numerous testimonies of women suffering
from adverse events, including mesh exposure and systemic
conditions, such as autoimmune disease, chronic pain and
fatigue.10,11 In the USA, there have been successful lawsuits
over complications following surgery with mesh for pelvic
organ prolapse, and there is media and public concern
about the use of mesh in urogynaecological surgery gener-
ally.12
A number of recent population-based studies have
reported on the long-term risk of removal and reoperation
following mesh sling insertion.13–15 However, only one
study has looked at the incidence of autoimmune disease
after vaginal mesh surgery. That study, which was carried
out in New York State, compared 1500 women who had
mesh surgery for pelvic prolapse with women who had
vaginal hysterectomy for benign gynaecological conditions
or colonoscopy, and did not find evidence of an associa-
tion.16
The aim of our study was to test the hypothesis that
there is no difference in the 10-year incidence of certain
systemic conditions, including autoimmune disease,
fibromyalgia and myalgic encephalomyelitis, between
women who have urinary incontinence surgery using mesh
and those who have urinary incontinence surgery without
mesh.
Methods
We used administrative hospital records to identify all
women who had first-time urinary incontinence surgery in
the English NHS between 2006 and 2013, and evaluated
the incidence of subsequent admissions with systemic dis-
ease within 10 years of the initial surgery.
Data sources
Data on all inpatient admissions to NHS hospitals in Eng-
land from April 2002 to March 2019 were extracted from
Hospital Episode Statistics, an administrative database with
records including patient demographics, dates of admission
and discharge, diagnostic and procedure information, and
date of death. Procedures for stress urinary incontinence
were identified using Office for Population Censuses and
Surveys Classification of Interventions and Procedures
Version 4 (OPCS-4) codes (Table S1).17
Cohort selection and outcome definition
All women who had a first-time urinary continence surgery
with or without mesh between 1 April 2006 and 31 March
2013 were eligible for inclusion. The start of the inclusion
period was chosen as mesh-specific OPCS-4 codes only
became available in 2006, and the end was chosen to allow
at least 5 years of follow up for each patient. Mesh surg-
eries evaluated included tension-free vaginal tape or tran-
sobturator tape insertion; non-mesh surgeries included
colposuspension and non-mesh slings (see Table S1).
Women were excluded if they had a record of previous
urinary incontinence surgery in a record of a hospital
admission in the 3 years before surgery (mesh or non-
mesh surgery, or use of a bulking agent; see Table S1). We
also excluded women who had a record of autoimmune
disease, fibromyalgia or myalgic encephalomyelitis in the
same period to ensure as much as possible that our out-
come reflects the first recording of these conditions.
The outcome was time from urinary continence surgery
to the date of the hospital admission with the first record-
ing of a diagnostic code indicating the presence of at least
one of 29 autoimmune diseases, fibromyalgia, or myalgic
encephalomyelitis, coded according to International Classi-
fication of Diseases version 10 (see Table S2).18
A woman’s ethnicity was retrieved from the record of
the admission during which the urinary incontinence sur-
gery took place. If the ethnicity information was not avail-
able in that record, but was available in another record,
information from that record was used instead. The Indices
of Multiple Deprivation are an area-based deprivation mea-
sure and were grouped into quintiles and used to measure
socio-economic deprivation.19 The number of pre-existing
comorbid conditions at the point of surgery was generated
using the algorithm developed by the Royal College of Sur-
geons of England to identify conditions that would con-
tribute to a patient’s Charlson Score,20 applied to records
of the admission with the urinary incontinence surgery and
all admissions in the three preceding years.
Statistical methods
Patient characteristics (ethnicity, age, deprivation quintile,
number of pre-existing comorbidities) and year of surgery
were described according to type of surgery, using percent-
ages and means.
We estimated the cumulative incidence of systemic con-
ditions, considering death as a competing event. Follow up
for each woman ended at the admission during which one
of the defined systemic conditions was recorded, at the end
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of the study period (31 March 2019), or after 10 years of
follow up, or death; whichever happened first. A Fine–Gray
competing risks regression model was used to test the dif-
ference in the cumulative incidence and to estimate the
subdistribution hazard ratio (HR) associated with mesh
compared with non-mesh surgery, with adjustment for dif-
ferences in patient characteristics between the surgery
groups in age, ethnicity, socio-economic deprivation, num-
ber of pre-existing comorbidities and year of operation.21
The subdistribution HR can be interpreted as a measure of
relative risk: a value of 1 implies no association, a value
greater than 1 indicates an increased incidence, and a value
below 1 indicates a decreased incidence, with mesh surgery.
Patients with missing data for the patient characteristics
included in the regression were excluded when estimating
the adjusted results. However, we carried out a sensitivity
analysis using multiple imputation with chained equations
to deal with the missing ethnicity data.22 Model coefficients
were obtained from ten imputed data sets, pooled using
Rubin’s rules. A second sensitivity analysis was carried out
to investigate the impact of restricting the outcome to
autoimmune diseases only.
Results
A total of 95 318 women were identified who had a first-
time urinary incontinence procedure with mesh and 3674
women who had a procedure without mesh between 2006
and 2013. After excluding 6656 women with a systemic
condition recorded in their surgery admission or in the
three preceding years, 88 947 women who had mesh sur-
gery and 3389 women who had non-mesh surgery were
included.
The total numbers of women having first-time mesh sur-
gery increased every year until 2008 and then gradually
decreased (Table 1; Figure S1). The annual numbers of
non-mesh surgeries fell throughout the inclusion period.
The women who had mesh and non-mesh surgeries
were very similar with respect to age, ethnicity, pre-
existing comorbidities and deprivation (Table 1). The
average age at surgery was 53.1 years for women who had
a mesh procedure and 52.2 years for women who had a
non-mesh procedure. Of the women who had a mesh
procedure, 20.2% had a pre-existing comorbid condition
compared with 21.9% of women who had a non-mesh
procedure. The frequency of missing data was very low,
with less than 1% missing data for comorbidities and
deprivation, less than 2% for age and less than 3% for
ethnicity. Eight women with subsequent systemic disease
were excluded from the analyses because date of readmis-
sion was missing.
The median follow-up duration mesh was 8.7 years (in-
terquartile range 6.8–10.0 years) for women who received
incontinence surgery with mesh and 9.9 years (interquartile
range 7.4–10.0 years) for women who had incontinence
surgery without mesh. The reasons for ending follow up
were similar between women who had mesh and non-mesh
surgery: 89.0% of women who had a mesh procedure and
88.2% of women who had a non-mesh procedure exited
the study before death or first record of a systemic condi-
tion (Table S3). Of the 6294 women who had a first record
of a systemic condition, the most common were rheuma-
toid arthritis (26.0% of women), polymyalgia rheumatica
(13.9%) and psoriasis vulgaris (10.1%) (Table S4). Myalgic
encephalomyelitis was observed in 4.7% and fibromyalgia
in less than 1.0% of these women. There were very small
differences in the distribution of the specific conditions
Table 1. Characteristics of patients analysed by type of surgery
Mesh group Non-mesh group
88 996 3432
Follow up (years), median (IQR) 8.7 (6.8–8.7) 9.9 (7.4–9.9)
Year of operation, n (%)
2006 5410 (6.1) 728 (21.3)
2007 11 823 (13.3) 618 (18.1)
2008 13 129 (14.8) 486 (14.2)
2009 12 850 (14.4) 400 (11.7)
2010 12 317 (13.8) 341 (9.9)
2011 11 803 (13.3) 294 (8.6)
2012 11 060 (12.4) 282 (8.2)
2013 10 604 (11.9) 283 (8.1)
Missing 0 (0.0) 0 (0.0)
Age at time of operation
(years), average  SD
53.1  12 52.2  12
Missing, n (%) 41 (0.0) 43 (1.3)
Socioeconomic deprivation, national quintiles, n (%)
1 Most deprived 14 590 (16.4) 621 (18.1)
2 16 868 (19.0) 664 (19.4)
3 18 746 (21.1) 683 (19.9)
4 19 316 (21.7) 720 (20.9)
5 Least deprived 19 059 (21.4) 713 (20.8)
Missing 417 (0.5) 31 (0.9)
Number of comorbidities, n (%)
0 70 973 (79.8) 2681 (78.1)
1 15 550 (17.5) 649 (18.9)
2 2070 (2.3) 77 (2.2)
3+ 403 (0.5) 25 (0.7)
Missing 0 (0.0) 0 (0.0)
Ethnicity, n (%)
White 82 807 (93.1) 3182 (92.9)
Asian/Asian British 1988 (2.2) 83 (2.3)
Black/Black British 7047 (0.8) 47 (1.3)
Other 1317 (1.5) 54 (1.6)
Missing 2177 (2.5) 66 (1.9)
IQR, interquartile range; SD, standard deviation.
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between the women who had mesh and non-mesh proce-
dures.
The cumulative incidence of autoimmune disease,
fibromyalgia or myalgic encephalomyelitis was estimated to
be 3.6% at 5 years and 8.1% at 10 years in women who
had a mesh procedure, and 4.0% and 9.0%, respectively, in
those who had a non-mesh procedure (unadjusted HR
0.89, 95% CI 0.79–1.00, P = 0.06; Figure 1 and Table 2).
The estimates of the differences in the cumulative inci-
dence of systemic conditions results were similar when
regression modelling was used to adjust for differences in
patient characteristics (adjusted HR 0.89, 95% CI 0.78–
1.01; Table 3). Older age at first surgery, pre-existing
comorbidities and higher level of socio-economic depriva-
tion were all strong risk factors for the incidence of
systemic conditions, but operation year and ethnic back-
ground were not associated with it.
In the first sensitivity analysis we repeated the regression
modelling with multiple imputation to account for missing
ethnicity data. This change had very little effect on the esti-
mate of the difference between the surgery groups (adjusted
HR 0.89, 95% CI 0.79–1.00, P = 0.06; see Table S5). A sec-
ond sensitivity analysis, where the outcome was restricted
just to autoimmune diseases (excluding fibromyalgia and
myalgic encephalomyelitis) also produced near-identical
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Figure 1. Cumulative incidence of autoimmune disease, fibromyalgia
or myalgic encephalomyelitis according to surgery type, with death as
competing event.
Table 2. Cumulative incidence of autoimmune disease, fibromyalgia
or myalgic encephalomyelitis by type of surgery
Mesh group Non-mesh group
Number of patients at risk
At time of surgery 88 947 3389
At 1 year 88 258 3351
At 5 year 84 110 3192
At 10 year 29 123 1678
Cumulative incidence of systemic diseases, % (95% CI)
At 1 year 0.6 (0.5–0.6) 0.7 (0.4–1.0)
At 5 year 3.6 (3.5–3.7) 4.0 (3.4–4.7)
At 10 year 8.1 (7.9–8.3) 9.0 (8.0–10.1)
HR (95% CI) 0.89 (0.79–1.01), P = 0.06
Cumulative incidence of autoimmune disease only, % (95% CI)
At 1 year 0.6 (0.5–0.6) 0.7 (0.4–1.0)
At 5 year 3.4 (3.3–3.6) 3.9 (3.3–4.6)
At 10 year 7.7 (7.5–7.9) 8.7 (7.7–9.7)
HR (95% CI) 0.88 (0.78–0.99), P = 0.04
Table 3. Hazard ratios expressing the impact of patient
characteristics on cumulative incidence of autoimmune disease,
fibromyalgia or myalgic encephalomyelitis by type of surgery
































Asian/Asian British 1.08 (0.92–1.26)
Black/Black British 0.82 (0.61–1.10)
Other 1.06 (0.87–1.29)
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We did not find evidence that the use of a synthetic mesh
sling in stress urinary incontinence surgery increased the
long-term risk of autoimmune disease, fibromyalgia or
myalgic encephalomyelitis, compared with non-mesh
incontinence surgery. The results were very similar when
the outcome was restricted to autoimmune disease. Older
age at surgery, the presence of pre-existing comorbidities
and a higher level of socio-economic deprivation, were all
independently associated with increased long-term risk of
these diseases.
Strengths and limitations
Our study used national population-based data on all uri-
nary incontinence operations carried out in the English
NHS between 2006 and 2013. It presents a highly represen-
tative population with near-complete follow up, given that
only 3.4% of healthcare expenditure in England covers pro-
cedures outside the NHS provided by the private sector.23
The large study population allowed comparison of the inci-
dence of specific conditions between women who had mesh
or non-mesh surgery.
The procedure coding available in the English HES data
made it possible to distinguish urinary continence proce-
dures that used mesh and those that did not. A unique
strength of our study is that we were able to compare two
cohorts of women receiving different treatments for the
same condition, avoiding any confounding from differences
in underlying risk of systemic disease between women trea-
ted for different conditions. This is in contrast to the study
of the impact of vaginal mesh use in prolapse surgery on
autoimmune disease carried out in New York State, which
used women who had colonoscopy or hysterectomy as the
comparison groups.16 We only included women who were
reported to have had incontinence surgery. We additionally
excluded women if they had a record of autoimmune dis-
ease, fibromyalgia or myalgic encephalomyelitis in the
3 years before mesh surgery.
It could be argued that fibromyalgia and myalgic
encephalomyelitis should not be considered in epidemio-
logical studies alongside autoimmune disease, because they
may be sensitive to a different set of risk factors. However,
we included them to ensure that our results are relevant to
the concerns of women who had or are considering urinary
incontinence surgery. A sensitivity analysis only using
autoimmune disease as an outcome produced near-
identical results. Additionally, there were no material differ-
ences in the incidence of each of the specific conditions
included in the composite outcome between women who
had mesh and non-mesh surgery, confirming that our
results are robust to the definition of the outcome.
Our study is restricted to information available in the
records of hospital admissions. Our outcome therefore
includes conditions severe enough to have been recorded in
hospital records. There are no obvious reasons to expect
that the incidence of systemic conditions between the two
surgery groups would have been different if conditions
recorded in primary care or during outpatient visits had
been included. However, further research using primary
care records and outpatient visits is required to confirm
this assumption.
Comparison with other studies
Our results are in line with other studies in the same area.
The prevalence of autoimmune disease in the population is
estimated to be around 8%.24 Our finding of a 10-year
incidence of 8.1% with mesh surgery and 9.0% without
mesh is compatible with these estimates. Our estimates of
5-year cumulative incidence of 3.6% with mesh surgery
and 4.0% with non-mesh surgery are very similar to the
results of the New York State study, comparing outcomes
after mesh surgery for pelvic prolapse and vaginal hysterec-
tomy, which reported that around 3% of women had been
diagnosed with an autoimmune disease irrespective of the
procedure after an average follow up of 6 years.16 Mesh is
also commonly used in inguinal hernia repair. A study, also
carried out in New York State, that compared 30 000 men
who had hernia repair with about 80 000 men who had
a colonoscopy, found no increased risk of autoimmune
disease.25
It has been hypothesised that the introduction of syn-
thetic material could lead to an upregulation of inflamma-
tory mediators, which may lead to the development of
generalised symptoms.26 Another possible pathway is that
degradation and absorption of the synthetic material would
lead to toxic effects affecting the whole body. Our results
do not support these pathways as a mechanism linking the
use of synthetic mesh to systemic conditions.
In England, a national review was carried out to investi-
gate how the healthcare system had responded to patients
reporting poor outcomes after treatment with pelvic
mesh.10 One of the review’s key lessons, relevant in the
context of our study, was that in all countries where syn-
thetic mid-urethral mesh slings were used there has been a
lack of long-term monitoring of outcomes, without which
it is impossible for regulators, patients and their clinicians
to fully understand the harms and benefits of available
treatment options. Our study demonstrates that some of
these long-term outcomes can be evaluated promptly using
existing administrative hospital data. An expansion of this
work including data on primary care consultations and
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outpatient clinic visits is now a key priority, given that this
will allow a more complete evaluation, also including con-
ditions that were not recorded in hospital admissions.
Interpretation
What does our finding – that the use of mesh does not
increase the long-term risk of systemic conditions – mean
for urinary continence surgery? First, a recent population-
based follow-up study in Scotland comparing mesh and
non-mesh urinary incontinence surgery found lower risk of
immediate complications after mesh surgery and a similar
risk of further incontinence surgery and later complications
up to 5 years.13 Taken together with the results from the
present study, the evidence is that outcomes of urinary
incontinence surgery with and without the use of mesh are
very similar.
Second, we found that the long-term risk of systemic
disease was slightly higher in women who had surgical
treatment without mesh. However, this difference in risk
was not statistically significant and the actual difference in
risk was very small (<1% difference in the 10-year risk),
which supports our interpretation that the risks of systemic
disease are very similar, irrespective of whether or not
mesh was used.
Third, it has been recommended that national patient-
identifiable databases be set up to collect details of the
mesh slings at the time of the operation, in combination
with long-term adverse events and patient-reported out-
comes.10 However as outlined above, our results in combi-
nation with those of other epidemiological studies,13,15
suggest that such patient registries should have a wider per-
spective and include all types of urinary incontinence sur-
gery, irrespective of whether mesh is used.
Fourth, there remain questions about the use of surgery
for urinary incontinence itself. Urinary incontinence can be a
devastating condition with a severe negative impact on a
woman’s quality of life. Surgery provides a further treatment
option if non-surgical treatments have not provided suffi-
cient improvement. Provision of comprehensive information
on the long-term benefits and risks from different treat-
ments, including from patient-reported outcomes, is needed
to allow patients to make fully informed treatment decisions.
Conclusion
We did not find an increased risk of systemic conditions in
women who had urinary incontinence surgery with a syn-
thetic mesh sling. The restrictions in the use of synthetic
mesh slings as treatment for urinary incontinence cannot
be justified on the basis of concerns related to increased
long-term risks of autoimmune disease, fibromyalgia or
myalgic encephalomyelitis. Further comparative evidence
from other settings, such as primary care, and on long-
term patient-reported outcomes, is needed to give women
considering surgery a complete picture of the likely out-
comes from different treatments.
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